huge financial burden of treatment arises. It is often arises out of ignorance & misconceptions, rather than any reality. In India the fight against cancer often becomes tough for lack of knowledge about lifestyle & societal practices while researchers are suggesting that 30% of cancer can be prevented by a little awareness and changes in lifestyle. After losing my brother in colon cancer because of such ignorance as an employee of a cancer institute I have decided to build a support group to make people aware with my small efforts in Kolkata, West Bengal. Methods: My brother lost his life to cancer for his disease was diagnosed at late stage. In his memory, I have built a small group with colleagues, neighbors & parents of my daughter's school for awareness and to recognize people early signs and symptoms, thus enabling them to seek treatment at an early stage. During the year 2014-2016 we have arranged 60 camps in schools, NGOs, clubs and arranged small street acts among underprivileged areas. We have built a small fund and donated Rs 10 per family per week and also helped 13 economically poor cancer patients in their disease diagnosis and initial treatment procedure before they receive some Govt. aided grants for rest of the treatment. Results: In this venture we have gathered many blessings, co workers, societies, school children even cancer survivors. Through awareness camps we have found many people who are in early stages of cancer and totally ignorant about the disease. Some are seeking treatment from quacks providing homeopathic treatment or some don't want to do FNAC for it will spread their disease. We brought them under standard treatment protocol. Also from our small endeavor we have helped 13 cancer patients, 2 colon, 5 breast, 3 paediatric cancer and 3 leukemia patients in their disease diagnosis and initial treatment procedure. Conclusions: In the changing aspect of the disease cancer, proper awareness, timely diagnosis and prompt medical attention could bring ray of hope and can also cure the disease. Let us make small endeavors in our surroundings so that no one has to lose their loved ones.

No abstract

The objective of this study was to evaluate the cost-effectiveness of pegfilgrastim (Peg-G) and daily filgrastim (Fil-G) for the primary prophylaxis against febrile neutropenia (FN) in patients with non-Hodgkin lymphoma (NHL) who received cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) therapy. We developed a decision analytical model reflecting the clinical processes of NHL patients who received first CHOP therapy. The probabilities at each clinical endpoint were obtained from published sources. To estimate the costs and duration of FN treatment, we analyzed the medical records of NHL patients in hospitals participating in this study. The costs of Peg-G and Fil-G were calculated according to the National Health Insurance drug price list. We assessed an incremental cost-effectiveness ratio (ICER) for a single dose of Peg-G versus 11-days of Fil-G from the perspective of health insurance payers. The sensitivity and robustness of this model were validated by the tornado-diagram and Monte Carlo Method. The costs associated with primary prophylaxis with a single dose of Peg-G and 11-days of Fil-G were 109,628 JPY and 109,243 JPY, respectively. The quality adjusted life years (QALYs) associated with the two strategies were 0.0339 QALYs and 0.0337 QALYs, respectively. The ICER for the Peg-G versus Fil-G was 2,788,571 JPY per QALY. The tornado-diagram revealed that the main influential factors included the cost of Peg-G, number of Fil-G doses, and cost of Fil-G. Monte Carlo simulation revealed an 18.3 probability that Peg-G was cost-effective compared with Fil-G. A single dose of Peg-G was cost-effective compared with 11-days of Fil-G.

No abstract